Meiying Zhu
Overview
Explore the profile of Meiying Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Zhao L, Gao F, Meng Y, Yang J, Zhu M, et al.
Curr Med Chem
. 2025 Feb;
PMID: 39995133
In most advanced cancers, standard medical treatments are generally employed. With the emergence of Antibody-Drug Conjugates (ADCs), more optimal therapeutic methods have become available for treating tumors. ADC is composed...
2.
Meng Y, Wang X, Yang J, Zhu M, Yu M, Li L, et al.
Discov Oncol
. 2024 Aug;
15(1):327.
PMID: 39090431
Small cell lung cancer (SCLC) is an extremely aggressive cancer with a relatively low median survival rate after diagnosis. Treatment options such as chemotherapy or combination immunotherapy have shown clinical...
3.
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L, et al.
J Transl Med
. 2024 Jul;
22(1):665.
PMID: 39020378
Metastatic breast cancer (mBC) poses a significant threat to women's health and is a major cause of malignant neoplasms in women. Human epidermal growth factor receptor (HER)3, an integral member...
4.
Chen L, Xie J, Zhu M, Wang D, Liu H, Zhan P, et al.
Transl Cancer Res
. 2024 Feb;
13(1):137-149.
PMID: 38410222
Background: The anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy has been extensively used in patients with non-small cell lung cancer (NSCLC) in which the tumors are...
5.
Wang L, Li M, Yang H, Dai F, Xie N, Li L, et al.
Aging (Albany NY)
. 2024 Feb;
16(4):4014-4032.
PMID: 38393698
Background: Breast cancer (BC) is a heterogeneous tumor with a variety of etiology and clinical features. Antibody-dependent cell phagocytosis (ADCP) is the last step of immune checkpoint inhibition (ICI), and...
6.
Meng Y, Zhu M, Yang J, Wang X, Liang Y, Yu M, et al.
Curr Cancer Drug Targets
. 2024 Jan;
24(9):910-919.
PMID: 38279718
Leptomeningeal metastasis (LM) is a serious and often fatal complication in patients with advanced lung cancer, resulting in significant neurological deficits, decreased quality of life, and a poor prognosis. This...
7.
Zhao J, Zhu M, Jiang H, Shen S, Su X, Shi Y
Sci Rep
. 2023 May;
13(1):7592.
PMID: 37165053
No abstract available.
8.
Zheng H, Zhu M, Li W, Zhou Z, Wan X
Liver Int
. 2022 Mar;
42(5):1144-1157.
PMID: 35274813
Cholangiocarcinoma (CCA) is a severe malignancy originating from the bile duct and the second most common primary liver cancer. NF-kappa B interacting lncRNA (NKILA) is a functional lncRNA, which play...
9.
Duan L, Zhou Q, Feng Z, Zhu C, Cai Y, Wang S, et al.
Front Pharmacol
. 2022 Feb;
13:710099.
PMID: 35185555
Linezolid-induced thrombocytopenia (LIT) is the main factor limiting the clinical application of linezolid (LZD). The incidence and risk factors of LIT in neonatal patients were possibly different from other populations...
10.
Zhu J, Zhao Q, Qiu Y, Zhang Y, Cui S, Yu Y, et al.
Nutrients
. 2021 Aug;
13(8).
PMID: 34444874
This study was designed to examine the association of soy isoflavones (SI) intake with different body measurements indicative of obesity in Chinese adults of Shanghai, a population consuming foods rich...